Suppr超能文献

肺移植术后伏立康唑相关性骨膜炎表现为肥大性骨关节病:两例报告并文献复习。

Voriconazole-associated periostitis presenting as hypertrophic osteoarthropathy following lung transplantation report of two cases and review of the literature.

机构信息

Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 822, Charleston, SC 29401, USA.

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Medical University of South Carolina, Charleston, SC 29401, USA.

出版信息

Semin Arthritis Rheum. 2019 Oct;49(2):319-323. doi: 10.1016/j.semarthrit.2019.04.003. Epub 2019 Apr 25.

Abstract

BACKGROUND

Hypertrophic osteoarthropathy (HOA) is a syndrome characterized by abnormal proliferation of skin and osseous tissue frequently associated with underlying pulmonary disorders. Cardinal features include digital clubbing, periostitis and significant joint and bone pain. A number of recent reports have emerged of HOA and periostitis occurring in association with the antifungal agent voriconazole.

METHODS

We present two additional cases of voriconazole-induced HOA and periostitis in lung transplant recipients with a review the medical literature.

RESULTS

In both cases, symptoms were painful and severe enough to require opioid medication. Rapid improvement occurred within days of voriconazole cessation. A review of existing literature revealed an additional 17 cases of voriconazole-induced HOA and periostitis in lung transplant patients.

CONCLUSION

We highlight the importance of recognizing the association of voriconazole with painful HOA and periostitis in lung transplant patients receiving antifungal therapy. Management of this painful condition involves cessation of voriconazole therapy, which may necessitate alternative anti-fungal drug therapies as well as adjustment of immunosuppressive drug dosage since voriconazole is a strong drug-inducer.

摘要

背景

肥厚性骨关节病(HOA)是一种以皮肤和骨骼组织异常增生为特征的综合征,常与肺部疾病有关。主要特征包括指(趾)端鼓槌状畸形、骨膜炎和明显的关节和骨痛。最近有许多报告称,抗真菌药物伏立康唑可引起 HOA 和骨膜炎。

方法

我们报告了两例肺移植患者因伏立康唑引起的 HOA 和骨膜炎,并对文献进行了回顾。

结果

在这两种情况下,症状都很疼痛,需要使用阿片类药物。在停止伏立康唑治疗后几天内迅速改善。对现有文献的回顾显示,在肺移植患者中,有 17 例因伏立康唑引起的 HOA 和骨膜炎。

结论

我们强调了在接受抗真菌治疗的肺移植患者中识别伏立康唑与疼痛性 HOA 和骨膜炎之间关联的重要性。这种疼痛状况的治疗包括停止伏立康唑治疗,这可能需要替代抗真菌药物治疗,以及调整免疫抑制剂药物剂量,因为伏立康唑是一种强效的药物诱导剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验